[Special Stock] JinMatrix Highlights Core Technology of COVID-19 Vaccine Platform... Expecting 100% Protection Effectiveness

[Asia Economy Reporter Hyungsoo Park] As COVID-19 cases rise again, JinMatrix's stock price is also showing an upward trend.

At 2:06 PM on the 14th, JinMatrix was trading at 8,850 KRW, up 12.6% from the previous day.

JinMatrix is developing a novel coronavirus vaccine using its core technology, the chimeric adenovirus vector platform (Chim-Ad), in response to the global COVID-19 pandemic. After developing four candidate substances and collaborating with the internationally accredited International Vaccine Institute (IVI) to conduct efficacy evaluations, they confirmed excellent cross-protection effects against variant virus strains, including the Delta variant.

The COVID-19 vaccine candidate 'GM-ChimAd-CV' was selected for the non-clinical support project of the COVID-19 Therapeutics and Vaccine New Drug Development Project Group. The plan is to complete non-clinical trials and proceed with rapid clinical development to secure a domestically produced COVID-19 vaccine urgently needed by society.

The chimeric adenovirus vector platform (Chim-Ad) is a fusion of human adenovirus serotype 5 (Ad5) and a rarely found human adenovirus serotype (Rare type). It is a proprietary adenovirus vector core technology that improves the issues of the existing Ad5 vector-based platform (pre-existing immunity) and enhances vaccine productivity and immune induction capability.

JinMatrix is developing effective vaccine candidates based on the chimeric adenovirus vector platform. It is being utilized for premium vaccine development against various emerging infectious disease viruses.

In March of this year, they developed and filed a patent for a universal vaccine candidate against COVID-19 variants through their vaccine development core platform.

This candidate is characterized as a dual-antigen-based vaccine using the coronavirus 'spike' surface antigen protein and the 'nucleocapsid' internal antigen protein. In immunogenicity comparison tests on mice, the candidate showed not only superior neutralizing antibody levels compared to RNA-based commercial vaccines but also 100% virus protection efficacy, and confirmed more than twice the superior T-cell immune induction capability.

An adjuvant is used to rapidly and strongly induce immune responses to vaccine antigens and to extend the duration of immunity. Currently, aluminum salts used in most vaccines excel at inducing humoral immunity by forming antibodies against antigens but have the drawback of not inducing cellular immune responses. Various adjuvants are being developed to overcome these limitations.

JinMatrix is utilizing Genetic adjuvant technology, which fuses ligands that bind to Toll-like receptors (TLR) on antigen-presenting cells at the genetic level with vaccine antigens to activate the immune system, for the development of high-efficacy vaccines.

This content was produced with the assistance of AI translation services.